Pivotree Inc. (CVE:PVT – Free Report) – Research analysts at Cormark decreased their FY2024 earnings per share estimates for Pivotree in a note issued to investors on Thursday, November 14th. Cormark analyst J. Pytlak now expects that the company will earn ($0.45) per share for the year, down from their previous estimate of ($0.28). Cormark has a “Market Perform” rating on the stock. The consensus estimate for Pivotree’s current full-year earnings is $0.08 per share. Cormark also issued estimates for Pivotree’s FY2025 earnings at $0.03 EPS.
Separately, Canaccord Genuity Group dropped their price objective on Pivotree from C$1.25 to C$1.00 in a research note on Thursday. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of C$2.38.
Pivotree Stock Up 3.3 %
PVT stock opened at C$0.93 on Monday. The company’s 50-day moving average price is C$1.08 and its 200 day moving average price is C$1.24. The company has a market cap of C$24.47 million, a P/E ratio of -2.58 and a beta of 0.22. The company has a current ratio of 2.80, a quick ratio of 1.95 and a debt-to-equity ratio of 0.73. Pivotree has a 52 week low of C$0.88 and a 52 week high of C$2.20.
About Pivotree
Pivotree Inc designs, integrates, deploys, and manages digital platforms in commerce, data management, and supply chain for retail and branded manufacturers in Canada and internationally. The company offers infrastructure deployment, data transaction, subscription license, system and application triage and support, configuration management, and security services, as well as provides web and application hosting services.
Recommended Stories
- Five stocks we like better than Pivotree
- Bank Stocks – Best Bank Stocks to Invest In
- Warren Buffett, Cathie Wood Own Nu Holdings, Should You?
- What Are Dividend Champions? How to Invest in the Champions
- MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?
- What Investors Need to Know About Upcoming IPOs
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Receive News & Ratings for Pivotree Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pivotree and related companies with MarketBeat.com's FREE daily email newsletter.